Novo Nordisk Faces $46 Billion Windfall Threatened by Wegovy Missteps and Eli Lilly’s Rise

Novo Nordisk’s weight-loss drug Wegovy, once hailed as a breakthrough obesity treatment, is facing stiff competition from Eli Lilly’s Zepbound, highlighting critical missteps in Novo’s market strategy. Despite generating an impressive $46 billion in profits since Wegovy’s U.S. launch in mid-2021, Novo now struggles to maintain its dominance in the growing obesity treatment market.

Key Strategic Errors
Novo misjudged the U.S. market, launching Wegovy without ensuring sufficient supply or robust health insurance coverage, despite internal warnings. With costs reaching $1,300 per month, many patients could not afford the treatment, driving some to cheaper alternatives. Analysts and former employees revealed that Novo’s leadership underestimated demand, leading to supply shortages and frustrated patients.

By contrast, Eli Lilly entered the market with ample supplies of its competing drug Zepbound, priced lower at $1,080 per month. Lilly also secured better discounts for uninsured patients, further boosting its market share.

Leadership Shakeups and Pricing Backlash
Novo’s U.S. chief Doug Langa pushed for an early Wegovy launch, ignoring advice to delay until stock levels and insurance coverage improved. This decision, coupled with inflexible pricing negotiations with insurers, alienated pharmacy benefit managers. Novo has since announced leadership changes, including the ousting of CEO Lars Fruergaard Jorgensen, in an effort to restore investor confidence.

Future Challenges
While clinical trials showed Wegovy could help patients lose 16% of body weight, Novo’s conservative forecasts limited its ability to meet demand. Eli Lilly’s aggressive market entry and creative pricing strategies are now forcing Novo to rethink its approach. Analysts warn that Novo risks losing its leadership position unless it adapts to market realities.